Fund Category Thematic (Equity)
Investment Objective The scheme provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. The Scheme does not guarantee/indicate any returns. There can be no assurance that the schemes' objectives will be achieved.
| Fund Details | |
|---|---|
| Fund Manager: | Mr. Dhaval Shah & Mr. Dhaval Joshi |
| Managing Fund Since: | July 11, 2019 & November 21, 2022 |
| Experience in Managing the Fund: | 3.9 Years & 0.5 Years |
| Date of Allotment: | Jul 11, 2019 |
| Type of Scheme: | An open ended equity scheme investing in Pharma and Healthcare Services Sector |
| Application Amount for fresh subscription: |
1,000 (plus in multiplies of 1) |
| Min. Addl. Investment: | 1,000 (plus in multiplies of 1) |
| SIP: | Monthly: Minimum 500/- |
| NAV of Plans / Options () | $Income Distribution cum capital withdrawal |
| Regular Plan | |
| Growth: | 19.0400 |
| IDCW$: | 15.2300 |
| Direct Plan | |
| Growth: | 20.3400 |
| IDCW$: | 16.2800 |
| Benchmark: | S&P BSE Healthcare TRI |
| Monthly Average AUM: | 469.23 Crores |
| AUM as on last day: | 488.68 Crores |
| Load Structure (as % of NAV) (Incl. for SIP) | |
| Entry Load: | Nil |
| Exit Load: | For redemption/switchout of units on or before 30 days from the date of allotment:1.00% of applicable NAV. For redemption/switch-out of units after 30 days from the date of allotment: Nil |
| Other Parameters | |
| Standard Deviation: | 15.54% |
| Sharpe Ratio: | 0.52 |
| Beta: | 0.92 |
| Portfolio Turnover: | 0.35 |
| Total Expense Ratio (TER) Including additional expenses and goods and service tax on management fees. |
|
| Regular | 2.45% |
| Direct | 1.10% |
Note: Standard Deviation, Sharpe Ratio & Beta are calculated on
Annualised basis using 3 years history of monthly returns. Risk Free Rate assumed to be 6.9% (FBIL Overnight MIBOR as on 30 June
2023) for calculating Sharpe Ratio
Data as on 30th June 2023 unless otherwise specified
| Portfolio Holdings | ||
|---|---|---|
| Issuer | % to net Assets |
Rating |
| Pharmaceuticals & Biotechnology | 76.15% | |
| Sun Pharmaceutical Industries Limited | 14.23% | |
| Torrent Pharmaceuticals Limited | 5.23% | |
| Dr. Reddys Laboratories Limited | 5.10% | |
| Aurobindo Pharma Limited | 4.99% | |
| Cipla Limited | 4.22% | |
| Zydus Lifesciences Limited | 4.15% | |
| Lupin Limited | 4.14% | |
| Strides Pharma Science Limited | 3.51% | |
| Alkem Laboratories Limited | 3.50% | |
| Biocon Limited | 3.25% | |
| J.B. Chemicals & Pharmaceuticals Limited | 2.98% | |
| Abbott India Limited | 2.49% | |
| Sanofi India Limited | 2.37% | |
| Mankind Pharma Ltd | 2.27% | |
| Ajanta Pharmaceuticals Limited | 2.16% | |
| ALEMBIC PHARMACEUTICALS LIMITED | 2.10% | |
| Natco Pharma Limited | 2.03% | |
| Eris Lifesciences Limited | 2.02% | |
| Indoco Remedies Limited | 2.02% | |
| Gland Pharma Limited | 2.02% | |
| Granules India Limited | 1.38% | |
| Healthcare Services | 17.70% | |
| Apollo Hospitals Enterprise Limited | 8.55% | |
| Fortis Healthcare Limited | 5.21% | |
| Global Health Ltd/India | 1.44% | |
| Vijaya Diagnostic Centre Limited | 1.39% | |
| Syngene International Limited | 1.11% | |
| Chemicals & Petrochemicals | 1.39% | |
| Vinati Organics Limited | 1.39% | |
| Retailing | 1.06% | |
| Medplus Health Services Limited | 1.06% | |
| Food Products | 0.89% | |
| Zydus Wellness Limited | 0.89% | |
| Cash & Current Assets | 2.83% | |
| Total Net Assets | 100.00% | |
# Scheme Benchmark, ## Additional Benchmark, * As on start of period considered above. For SIP calculations above, the data assumes the investment of 10000/- on 1st day of every month or the subsequent working day. Load & Taxes are not considered for computation of returns. Performance for IDCW option would assume reinvestment of tax free IDCW declared at the then prevailing NAV. CAGR returns are computed after accounting for the cash flow by using XIRR method (investment internal rate of return).Where Benchmark returns are not available, they have not been shown. Past performance may or may not be sustained in future. Returns greater than 1 year period are compounded annualized. IDCW are assumed to be reinvested and bonus is adjusted. Load is not taken into consideration. For SIP returns, monthly investment of equal amounts invested on the 1st day of every month has been considered.
Note: The exit load (if any) rate levied at the time of redemption/switch-out of units will be the rate prevailing at the time of allotment of the corresponding units. Customers may request for a separate Exit Load Applicability Report by calling our toll free numbers 1800-270-7000 or from any of our Investor Service Centers.
This page is a part of the July 2023 Factsheet of Aditya Birla Sun Life Mutual Fund. Click on http://empower.abslmf.com/ for the digital factsheet.
Mutual Fund investments are subject to market risks, read all scheme related documents carefully.
